Sansure Biotech Inc.

Shanghai Stock Exchange 688289.SS

Sansure Biotech Inc. EBIT for the year ending December 31, 2023: USD 61.72 M

Sansure Biotech Inc. EBIT is USD 61.72 M for the year ending December 31, 2023, a -81.79% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Sansure Biotech Inc. EBIT for the year ending December 31, 2022 was USD 338.94 M, a -17.55% change year over year.
Sansure Biotech Inc. EBIT for the year ending December 31, 2021 was USD 411.08 M, a -12.63% change year over year.
Sansure Biotech Inc. EBIT for the year ending December 31, 2020 was USD 470.50 M, a 7,010.00% change year over year.
Sansure Biotech Inc. EBIT for the year ending December 31, 2019 was USD 6.62 M, a 322.10% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Shanghai Stock Exchange: 688289.SS

Sansure Biotech Inc.

CEO	Mr. Lizhong Dai
IPO Date	Aug. 28, 2020
Location	China
Headquarters	No. 680, Lusong Road
Employees	2,006
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Sansure Biotech Inc. develops and sells upstream nucleic acid extraction kits, real time PCR diagnostic and research kits, and fluorescence systems in China and internationally. The company offers novel coronavirus nucleic acid diagnostic kits; viral hepatitis and AIDS, blood screening, and extraction kits; cancer-related biomarkers; and kits for respiratory tract diseases, STDs, digestive tract diseases, prenatal and postnatal care, and genetic diseases, as well as instruments and other consumables. It serves hospitals and laboratories. The company was founded in 2008 and is based in Changsha, China.

Key trends

Past 5 years